Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector

article i nfo Drug development is the lifeblood of pharmaceutical firms and a critical source of innovation in the healthcare industry. Pharmaceutical firms maintain their competitiveness by continuously developing and introducing new drugs, which requires an efficient new drug portfolio management process. However, the current literature does not elaborate on strategies pertaining to these new drug (product) portfolios (i.e., portfolios of drugs under development), nor does it provide the means with which to understand the future cash flow-generating potential of these portfolio strategies. To address this problem, we propose a set of generic descriptors of new drug portfolio strategies (i.e., portfolio breadth, portfolio depth, blockbuster strategy, and stages of the drug development process) and relate these descriptors to Tobin's q, a forward- looking measure of shareholder expectations. The results of a latent class regression analysis show that shareholder expectations of firms with broad new drug portfolios and potential blockbusters are positive. For most firms, shareholders focus on the final stage of the drug development process and deemphasize portfolio depth. In contrast, for a minority of mostly small firms, shareholders seem to value the earlier stages of the drug development process and stress portfolio depth.

[1]  A. F. Smith,et al.  Statistical analysis of finite mixture distributions , 1986 .

[2]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[3]  Walter W. Powell,et al.  Networks and Organizations , 2006 .

[4]  E. Fama,et al.  The Adjustment of Stock Prices to New Information , 1969 .

[5]  J. Goldenberg,et al.  The NPV of bad news , 2007 .

[6]  Tammo H. A. Bijmolt,et al.  Country and Consumer Segmentation: Multi-Level Latent Class Analysis of Financial Product Ownership , 2004 .

[7]  Hun Lee,et al.  What matters about internationalization: a market-based assessment , 2005 .

[8]  Mary W. Sullivan,et al.  The Measurement and Determinants of Brand Equity: A Financial Approach , 1993 .

[9]  B. Kogut,et al.  INTERFIRM COOPERATION AND STARTUP INNOVATION IN THE BIOTECHNOLOGY INDUSTRY. , 1993 .

[10]  F. Black.  The Magic in Earnings: Economic Earnings versus Accounting Earnings , 1980 .

[11]  S. Dutta,et al.  Portfolios of Interfirm Agreements in Technology-Intensive Markets: Consequences for Innovation and Profitability , 2004 .

[12]  Tasadduq A. Shervani,et al.  Marketing, Business Processes, and Shareholder Value: An Organizationally Embedded View of Marketing Activities and the Discipline of Marketing , 1999 .

[13]  Cynthia A. Montgomery,et al.  Tobin's q and the Importance of Focus in Firm Performance , 1988 .

[14]  F. Scherer,et al.  The link between gross profitability and pharmaceutical R&D spending. , 2001, Health affairs.

[15]  R. Bordley.  Determining the Appropriate Depth and Breadth of a Firm's Product Portfolio , 2003 .

[16]  George B. Macready,et al.  Concomitant-Variable Latent-Class Models , 1988 .

[17]  V. Kumar,et al.  Using a customer-Level marketing strategy to enhance firm performance: A review of theoretical and empirical evidence , 2005 .

[18]  E. H. Bowman,et al.  Strategy through the Option Lens: An Integrated View of Resource Investments and the Incremental-Choice Process , 1993 .

[19]  Robert G. Cooper,et al.  Portfolio Management for New Products (Управление портфелем новых продуктов) , 1998 .

[20]  Karl T. Ulrich,et al.  Special Issue on Design and Development: Product Development Decisions: A Review of the Literature , 2001, Manag. Sci..

[21]  Ming Ding,et al.  Structuring the New Product Development Pipeline , 2002, Manag. Sci..

[22]  G. Tellis,et al.  Understanding and Managing International Growth of New Products , 2004 .

[23]  E. Kahya.  Prediction of Business Failure: A Funds Flow Approach , 1997 .

[24]  Anurag Sharma,et al.  Linking Product Development Outcomes to Market Valuation of the Firm: The Case of the U.S. Pharmaceutical Industry* , 2004 .

[25]  Venkatesh Shankar,et al.  Asymmetric New Product Development Alliances: Win-Win or Win-Lose Partnerships? , 2007, Manag. Sci..

[26]  John A. Quelch,et al.  Extend Profits, Not Product Lines , 1994 .

[27]  B. Everitt,et al.  Finite Mixture Distributions , 1981 .

[28]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[29]  Tasadduq A. Shervani,et al.  Market-Based Assets and Shareholder Value: A Framework for Analysis , 1998 .

[30]  Laura B. Cardinal,et al.  The location of corporate research and innovative productivity in the US pharmaceutical industry , 2000 .

[31]  Pilar Carbonell,et al.  The impact of market characteristics and innovation speed on perceptions of positional advantage and new product performance , 2006 .

[32]  Peter Hwang,et al.  MULTINATIONALS' DIVERSIFICATION AND THE RISK-RETURN TRADE-OFF , 1993 .

[33]  J. W. Hutchinson,et al.  Unobserved Heterogeneity as an Alternative Explanation for 'Reversal' Effects in Behavioral Research , 2000 .

[34]  Rolf Ulrich,et al.  Random search with unequal search rates: Serial and parallel generalizations of McGill's model , 1987 .

[35]  Marjorie B. Platt,et al.  A note on the use of industry-relative ratios in bankruptcy prediction , 1991 .

[36]  Rajdeep Grewal,et al.  Building Organizational Capabilities for Managing Economic Crisis: The Role of Market Orientation and Strategic Flexibility , 2001 .

[37]  Rajesh K. Chandy,et al.  From Invention to Innovation: Conversion Ability in Product Development , 2006 .

[38]  R. Chandy,et al.  Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals , 2003 .

[39]  Gary L. Lilien,et al.  Location, Location, Location: How Network Embeddedness Affects Project Success in Open Source Systems , 2006, Manag. Sci..

[40]  S. Dutta,et al.  Success in High-Technology Markets: is Marketing Capability Critical? , 1999 .

[41]  J. A. Miles,et al.  Principles of corporate finance: Richard Brealey and Stewart Myers, (Mcgraw-Hill Book Company, New York, 1981) pp. xxii + 794 , 1982 .

[42]  W. DeSarbo,et al.  A maximum likelihood methodology for clusterwise linear regression , 1988 .

[43]  M. Wedel,et al.  Market Segmentation: Conceptual and Methodological Foundations , 1997 .

[44]  Rajdeep Grewal,et al.  Strategic Responses to New Technologies and Their Impact on Firm Performance , 2004, Journal of Marketing.

[45]  Yadong Luo.  Product diversification in international joint ventures: performance implications in an emerging market , 2002 .

[46]  Venkatesh Shankar,et al.  Strategic Marketing Decision Models for the Pharmaceutical Industry , 2008 .

[47]  Glenn B. Voss,et al.  Aligning Innovation with Market Characteristics in the Nonprofit Professional Theater Industry , 2006 .

[48]  Harsha Aturupane.  Poverty, human development and growth : an emerging consensus? , 1994 .

[49]  R. Srinivasan,et al.  Dual Distribution and Intangible Firm Value: Franchising in Restaurant Chains , 2006 .

[50]  Laura B. Cardinal.  Technological Innovation in the Pharmaceutical Industry: The Use of Organizational Control in Managing Research and Development , 2001 .

[51]  A. Mahmoud,et al.  Product Development Priorities , 2006 .

[52]  R. Cooper,et al.  Portfolio management for new product development: results of an industry practices study , 2001 .

[53]  Laura B. Cardinal,et al.  Internal knowledge generation: the research laboratory and innovative productivity in the pharmaceutical industry , 2000 .

[54]  Robert G. Cooper,et al.  Benchmarking Best NPD Practices-II: Strategy, Resource Allocation and Portfolio Management Are the Focus of This Second in a Three-Part Series , 2004 .

[55]  Ron Sanchez,et al.  Modular Architectures in the Marketing Process , 1999 .

[56]  Berend Wierenga,et al.  The effect of the marketing-R&D interface on new product performance: The critical role of resources and scope ☆ , 2008 .

[57]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[58]  R. Sanchez.  Strategic flexibility in product competition , 1995 .

[59]  Z. Griliches.  Productivity, R&D, and the Data Constraint , 1998 .

[60]  A. Griffin.  PDMA Research on New Product Development Practices: Updating Trends and Benchmarking Best Practices , 1997 .

[61]  Harikesh S. Nair,et al.  Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations , 2004 .

[62]  William P. Putsis,et al.  An Empirical Analysis of Firms' Product Line Decisions , 1999 .

[63]  J. S. Evans.  STRATEGIC FLEXIBILITY FOR HIGH TECHNOLOGY MANOEUVRES: A CONCEPTUAL FRAMEWORK , 1991 .

[64]  R. Cooper,et al.  Benchmarking Best NPD Practices—II , 2004 .

[65]  Gregory S. Carpenter,et al.  Measuring Marketing Productivity: Current Knowledge and Future Directions , 2004 .

[66]  I. Cockburn,et al.  Measuring competence?: exploring firm effects in pharmaceutical research , 1994 .

[67]  R. Kerin,et al.  Exploring the brand value-shareholder value nexus for consumer goods companies , 1998 .

[68]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[69]  D. Bower.  New product development in the pharmaceutical industry: Pooling network resources , 1993 .

[70]  Sundar G. Bharadwaj,et al.  Information Technology Effects on Firm Performance as Measured by Tobin's q , 1999 .

[71]  Michel Wedel,et al.  Concomitant Variable Latent Class Models for Conjoint Analysis , 1994 .

[72]  H. Bozdogan.  Model selection and Akaike's Information Criterion (AIC): The general theory and its analytical extensions , 1987 .

[73]  H. Barkema,et al.  International Expansion Through Start-Up or Acquisition: A Learning Perspective , 1998 .

[74]  Stephen W. Pruitt,et al.  A Simple Approximation of Tobin's Q , 1994 .

[75]  D. Jamison,et al.  Product Development Priorities -- Disease Control Priorities in Developing Countries , 2006 .

[76]  R. Jacobson,et al.  Trading off between Value Creation and Value Appropriation: The Financial Implications of Shifts in Strategic Emphasis , 2003 .